Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Mirum Pharmaceuticals announced that the VISTAS Phase 2b study of volixibat in primary sclerosing cholangitis (PSC) met its primary endpoint, demonstrating a statistically significant reduction in pruritus. Treatment with volixibat resulted in a 2.72 point reduction from baseline on the Adult ItchRO scale, with a placebo-adjusted difference of 1.64 points (p<0.0001).
Key figures
- Drug Name
- Volixibat
- Phase Of Trial
- Phase 2b
- P value
- <0.0001
- Total patients
- 158
- Planned nda submission
- second half of 2026
- Primary cohort patients
- 111
- Primary reduction points
- -2.72
- Placebo adjusted difference
- -1.64
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.